Recent Pfizer Press Releases

(BUSINESS WIRE)--Pfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for the potential treatment of patients with breast cancer.Enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy designation is intended to expedite the development and review of a potential new medicinemore...

(BUSINESS WIRE)--Pfizer Consumer Healthcare (NYSE: PFE), makers of Advil®, is kicking off its Advil® Relief in Action campaign today that honors volunteers who don’t let pain get in the way of providing relief to others in need. Advil® Relief in Action celebrates the efforts of these tireless everyday heroes, as well as supports and contributes to the efforts of Habitat for Humanity and Wounded Warrior Project® (WWP), whose volunteers exemplify Relief in Action

(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission (EC) has granted conditional marketing authorization for BOSULIF® (bosutinib) in the European Union (EU) for the treatment of adult patients with chronic phase (CP), accelerated phase (AP) and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and

(BUSINESS WIRE)--Forget “50 is the new 40” or even “the new 30,” age 50 is about moving forward. That’s why YMCA of the USA (Y-USA) and Pfizer Inc launched 50 MOVING FORWARD, a healthy living plan designed to motivate adults 50 years and older with fresh ideas about behaviors that experts say are crucial to healthy aging: physical activity; preventive measures like screenings and vaccinations; healthy eating; and social interaction. Those who want

SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the REMINDER trial showing statistically significant risk reductions in the primary composite efficacy endpoint. The composite endpoint was defined as the time to first event of cardiovascular (CV) mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure (HF), sustained ventricular tachycardia or fibrillation, ejection fraction (EF) ≤40% after 1 month,

BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])in adults infected with human immunodeficiency virus (HIV). The results were presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, Ga. These data support planned regulatory

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, President and General Manager, Specialty Care and Oncology, at the Citi 2013 Global Healthcare Conference on Tuesday, February 26, 2013 at 4:35 p.m. Eastern Standard Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Citi 2013 Global Healthcare Conference” link in the Investor

(BUSINESS WIRE)--Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer’s patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed. The company brought a patent infringement action in April 2010 against the generic company Watson Laboratories, Inc—Florida (now known as Actavis) and three other Watson entities after

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company’s pneumococcal conjugate vaccine, Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes